Beovu

Chemical Namebrolucizumab–dbll
Dosage FormInjectable (intravitreal; 6 mg/0.05 mL)
Drug ClassMonoclonal antibodies
SystemOcular
CompanyNovartis
Approval Year2019

Indication

  • Beovu is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).
Last updated on 2/2/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?